Literature DB >> 33673034

Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies.

Inês C Brás1, Tiago F Outeiro1,2,3,4.   

Abstract

The accumulation of misfolded alpha-synuclein (aSyn) throughout the brain, as Lewy pathology, is a phenomenon central to Parkinson's disease (PD) pathogenesis. The stereotypical distribution and evolution of the pathology during disease is often attributed to the cell-to-cell transmission of aSyn between interconnected brain regions. The spreading of conformationally distinct aSyn protein assemblies, commonly referred as strains, is thought to result in a variety of clinically and pathologically heterogenous diseases known as synucleinopathies. Although tremendous progress has been made in the field, the mechanisms involved in the transfer of these assemblies between interconnected neural networks and their role in driving PD progression are still unclear. Here, we present an update of the relevant discoveries supporting or challenging the prion-like spreading hypothesis. We also discuss the importance of aSyn strains in pathology progression and the various putative molecular mechanisms involved in cell-to-cell protein release. Understanding the pathways underlying aSyn propagation will contribute to determining the etiology of PD and related synucleinopathies but also assist in the development of new therapeutic strategies.

Entities:  

Keywords:  Parkinson’s disease; alpha-synuclein; cell-to-cell transfer; neurodegeneration; prion-like spreading

Year:  2021        PMID: 33673034     DOI: 10.3390/cells10020375

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  15 in total

1.  Co-expression of APP/PS1 disrupts the distribution of brain lesions in a synucleinopathy transgenic mouse model (M83).

Authors:  Thierry Baron; Jean-Noël Arsac; Jérémy Verchère; Habiba Tlili; Claire Aufauvre; Dominique Bétemps
Journal:  Acta Neuropathol       Date:  2022-03-07       Impact factor: 17.088

2.  Path analysis of biomarkers for cognitive decline in early Parkinson's disease.

Authors:  Dmitri K Gramotnev; Galina Gramotnev; Alexandra Gramotnev; Mathew J Summers
Journal:  PLoS One       Date:  2022-05-13       Impact factor: 3.752

Review 3.  Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies.

Authors:  Sindhu Menon; Sabrina Armstrong; Amir Hamzeh; Naomi P Visanji; Sergio Pablo Sardi; Anurag Tandon
Journal:  Front Neurol       Date:  2022-05-09       Impact factor: 4.086

Review 4.  Alpha-Synuclein Aggregation Pathway in Parkinson's Disease: Current Status and Novel Therapeutic Approaches.

Authors:  Marija Vidović; Milena G Rikalovic
Journal:  Cells       Date:  2022-05-24       Impact factor: 7.666

Review 5.  Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside.

Authors:  Awanish Mishra; Ritam Bandopadhyay; Prabhakar Kumar Singh; Pragya Shakti Mishra; Neha Sharma; Navneet Khurana
Journal:  Metab Brain Dis       Date:  2021-08-13       Impact factor: 3.584

6.  Small Molecule Fisetin Modulates Alpha-Synuclein Aggregation.

Authors:  Rita Rosado-Ramos; Joana Godinho-Pereira; Daniela Marques; Inês Figueira; Tiago Fleming Outeiro; Regina Menezes; Cláudia Nunes Dos Santos
Journal:  Molecules       Date:  2021-06-02       Impact factor: 4.411

7.  Heat Shock Protein 70 as a Sex-Skewed Regulator of α-Synucleinopathy.

Authors:  Tarun N Bhatia; Rachel N Clark; Patrick G Needham; Kristin M Miner; Anuj S Jamenis; Elizabeth A Eckhoff; Nevil Abraham; Xiaoming Hu; Peter Wipf; Kelvin C Luk; Jeffrey L Brodsky; Rehana K Leak
Journal:  Neurotherapeutics       Date:  2021-09-15       Impact factor: 6.088

Review 8.  O-GlcNAcylation in health and neurodegenerative diseases.

Authors:  Byeong Eun Lee; Pann-Ghill Suh; Jae-Ick Kim
Journal:  Exp Mol Med       Date:  2021-11-26       Impact factor: 8.718

Review 9.  Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies.

Authors:  Pedro Magalhães; Hilal A Lashuel
Journal:  NPJ Parkinsons Dis       Date:  2022-07-22

Review 10.  Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?

Authors:  Victoria Sidoroff; Pam Bower; Nadia Stefanova; Alessandra Fanciulli; Iva Stankovic; Werner Poewe; Klaus Seppi; Gregor K Wenning; Florian Krismer
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.